Pharma Focus Europe

Scenic Biotech Partners with Bristol Myers Squibb for Research Collaboration

Thursday, May 02, 2024

Scenic Biotech, a leader in the field of modifier therapies for severe genetic disorders, has announced a research collaboration with Bristol Myers Squibb (NYSE: BMY) aimed at accelerating the development of drug targets owned by Bristol Myers Squibb. The collaboration will focus on identifying target biology for indication selection and expansion. Scenic Biotech will receive an upfront payment and potential additional payments based on achieving various research, development, and commercial milestones. The financial terms of the agreement have not been disclosed.

Scenic Biotech, expressed enthusiasm about the collaboration, stating, “Working with a world leader in drug discovery and development is an important validation of our Cell-Seq platform’s unique capability to link cellular pathways to drug targets. As we continue to advance our own pipeline of first-in-class disease-modifying therapies, we remain committed to harnessing the power of our ground-breaking approach to support our collaborators in crafting innovative medicines for patients with devastating conditions.”

This collaboration with Bristol Myers Squibb follows a previous strategic partnership with Genentech announced in 2020. Both collaborations utilize the Cell-Seq platform’s ability to provide genetic insights leading to the discovery and development of novel therapeutics. While Scenic Biotech primarily focuses on applying its Cell-Seq technology to identify modifier genes, the platform has also demonstrated its ability to map previously unexplored biological pathways and investigate disease biology.

 

Source: businesswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva